Apogee Therapeutics (APGE) Net Equity Issued and Repurchased (2023 - 2026)
Apogee Therapeutics (APGE) posted quarterly Net Equity Issued and Repurchased of $378.2 million for Q1 2026, up 459.42% quarter-over-quarter from $67.6 million in Q4 2025.
Apogee Therapeutics (APGE) Net Equity Issued and Repurchased (2023 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $378.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $378.2 million; the TTM figure through Mar 2026 stood at $465.8 million (up 950.0% YoY), while the FY2025 annual figure was $67.6 million, down 84.98% from the prior year.
- Net Equity Issued and Repurchased improved to $378.2 million in Q1 2026 per APGE's latest filing, from $67.6 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $450.5 million in Q1 2024 and bottomed at -$541000.0 in Q2 2024.
- Historically, Net Equity Issued and Repurchased has averaged $137.2 million across 4 years, with a median of $44.9 million in 2024.
- Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased soared 21179.81% — and 2025, when it surged 50.56%.
- Apogee Therapeutics' Net Equity Issued and Repurchased stood at -$213000.0 in 2023, then jumped by 21179.81% to $44.9 million in 2024, then surged by 50.56% to $67.6 million in 2025, then surged by 459.42% to $378.2 million in 2026.
- Business Quant data shows APGE's Net Equity Issued and Repurchased at $378.2 million in Q1 2026, $67.6 million in Q4 2025, and $20.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - | -728,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -728,000.00 |
| Jun 30, 2026 | -728,000.00 |
| Mar 31, 2026 | 378.17 Mn |
| Mar 31, 2026 | 378.17 Mn |
| Dec 31, 2025 | 67.60 Mn |
| Dec 31, 2025 | 67.60 Mn |
| Sep 30, 2025 | 20.00 Mn |
| Sep 30, 2025 | 20.00 Mn |
| Dec 31, 2024 | 44.90 Mn |
| Dec 31, 2024 | 44.90 Mn |
| Jun 30, 2024 | -541,000.00 |
| Jun 30, 2024 | -541,000.00 |
| Mar 31, 2024 | 450.50 Mn |
| Mar 31, 2024 | 450.50 Mn |
| Dec 31, 2023 | -213,000.00 |
| Dec 31, 2023 | -213,000.00 |